Laboratory Testing in Stroke: From Routine Workup to Rare Diagnoses
Laboratory testing in stroke serves multiple purposes: identifying modifiable risk factors, determining stroke etiology, guiding secondary prevention, monitoring therapeutic efficacy, and uncovering rare mimics or genetic conditions. While most patients require only routine metabolic workup, specialized testing is essential when clinical features suggest unusual etiologies—particularly in young patients, cryptogenic strokes, or atypical presentations.
🔹 Bottom Line: Laboratory Testing in Stroke
- Routine labs: Lipid panel (target LDL <70 mg/dL per TST), HbA1c, BMP, CBC for all ischemic stroke patients.
- Lp(a): Consider in cryptogenic stroke or premature atherosclerosis; elevated levels indicate residual risk despite statin therapy.
- Hypercoagulable panel: Reserve for young stroke (<50), cryptogenic with venous features, recurrent strokes, or clinical APS suspicion.
- D-dimer: Markedly elevated levels with multiterritory infarcts suggest Trousseau syndrome—pursue malignancy workup.
- Therapeutic monitoring: Platelet function assays, anti-Xa levels, and INR can assess antithrombotic efficacy and adherence.
- Rare diagnoses: Consider Fabry (young, posterior circulation), MELAS (cortical strokes, seizures, lactate), APS (miscarriages, clots), sickle cell (African descent, moyamoya pattern).
Part I: Routine Laboratory Testing
Lipid Panel
Dyslipidemia is a major modifiable risk factor for atherosclerotic stroke. The SPARCL trial demonstrated that high-dose atorvastatin (80 mg) reduced recurrent stroke by 16% in patients with recent stroke/TIA. The TST (Treat Stroke to Target) trial showed that targeting LDL <70 mg/dL reduced major cardiovascular events compared to a target of 90–110 mg/dL in patients with atherosclerotic stroke.
| Lipid Parameter | Optimal Target | Clinical Relevance |
|---|---|---|
| LDL Cholesterol | <70 mg/dL (atherosclerotic disease) <55 mg/dL (very high risk, ESC), otherwise <100 if no atherosclerotic disease |
Primary target; reduction lowers ischemic stroke risk; SPARCL, TST evidence |
| Total Cholesterol | <200 mg/dL | General cardiovascular risk marker |
| HDL Cholesterol | >40 mg/dL (men) >50 mg/dL (women) |
Low HDL associated with increased stroke risk; no proven benefit from pharmacologic elevation |
| Triglycerides | <150 mg/dL | Elevated TG contributes to residual risk; icosapent ethyl reduces CV events in hypertriglyceridemia (REDUCE-IT) |
| Non-HDL Cholesterol | <100 mg/dL | Captures all atherogenic lipoproteins; useful when TG elevated |
Lipoprotein(a) — Lp(a)
Lp(a) is a genetically determined, LDL-like particle that confers independent cardiovascular risk not modified by statins. Elevated Lp(a) (>50 mg/dL or >125 nmol/L) is associated with increased stroke and MI risk. Consider testing in:
- Cryptogenic stroke, especially with premature atherosclerosis
- Family history of early cardiovascular disease
- Recurrent events despite optimal LDL control
- Patients with borderline indications for aggressive lipid therapy
Limitation: No approved Lp(a)-lowering therapies yet, though antisense oligonucleotides (pelacarsen) are in phase 3 trials. Current management includes aggressive LDL reduction, PCSK9 inhibitors (modest Lp(a) lowering), and consideration of aspirin for primary prevention in high-risk individuals.
Glycemic Assessment
HbA1c reflects average glucose over 2–3 months and is diagnostic for diabetes (≥6.5%) or prediabetes (5.7–6.4%). Diabetes doubles stroke risk and worsens outcomes. Target HbA1c <7% for most stroke patients; individualize for elderly or those with hypoglycemia risk.
Admission glucose: Hyperglycemia at presentation (even without diabetes) is associated with larger infarct volumes and worse outcomes. Target glucose 140–180 mg/dL in the acute setting; avoid hypoglycemia.
Basic Metabolic Panel & CBC
Routine testing provides essential baseline data:
- Creatinine/eGFR: Guides contrast use, DOAC dosing, and identifies CKD as a stroke risk factor
- Electrolytes: Hyponatremia may occur with cerebral salt wasting; hyperglycemia affects osmolality
- Hemoglobin/Hematocrit: Anemia worsens outcomes; polycythemia increases viscosity
- Platelet count: Thrombocytopenia affects antiplatelet choice; thrombocytosis may be reactive or myeloproliferative
Part II: Inflammatory & Thrombotic Markers
C-Reactive Protein (hs-CRP)
High-sensitivity CRP is a marker of systemic inflammation and atherosclerotic risk. Elevated hs-CRP (>2 mg/L) identifies patients with “residual inflammatory risk” who may benefit from intensified therapy. The JUPITER trial showed that rosuvastatin reduced cardiovascular events in patients with elevated CRP even with normal LDL—though routine CRP-guided therapy remains debated in stroke.
Clinical utility: May help risk-stratify patients with borderline indications for statin therapy or identify those who might benefit from anti-inflammatory approaches (colchicine trials ongoing in stroke).
Erythrocyte Sedimentation Rate (ESR)
ESR is a nonspecific inflammatory marker with particular importance in suspected giant cell arteritis (GCA):
- When to order: Older patient (>50 years) with new headache, jaw claudication, scalp tenderness, visual symptoms, or unexplained constitutional symptoms
- Concerning threshold: ESR >50 mm/hr raises suspicion; >100 mm/hr highly concerning for GCA
- Action: If GCA suspected, start empiric steroids immediately and obtain temporal artery biopsy; do not delay treatment for biopsy
Also consider ESR/CRP in suspected CNS vasculitis, endocarditis, or systemic inflammatory conditions.
D-Dimer
D-dimer is not part of routine stroke workup but becomes important when cancer-associated thrombosis (Trousseau syndrome) is suspected:
🔴 Red Flags for Trousseau Syndrome
- Multiterritory infarcts (“Trousseau 3-vessel sign”)—simultaneous strokes in different vascular territories
- Unexplained weight loss, anorexia, or constitutional symptoms
- Migratory superficial thrombophlebitis
- Concurrent DVT/PE or unusual thrombosis sites
- Markedly elevated D-dimer (>2–3× upper limit of normal)
Action: If Trousseau suspected, pursue CT chest/abdomen/pelvis, age-appropriate cancer screening, and consider anticoagulation (LMWH often preferred over DOACs in active malignancy).
Part III: Antithrombotic Therapeutic Monitoring
Laboratory testing can assess whether antithrombotic therapy is effective and whether patients are adherent. This is particularly useful in patients with recurrent events despite therapy or when drug interactions/metabolism concerns exist.
| Medication | Assay | Interpretation | Clinical Use |
|---|---|---|---|
| Aspirin | Platelet function assay (VerifyNow Aspirin, PFA-100) | ARU <550 suggests adequate inhibition | Suspected non-adherence, aspirin “resistance,” recurrent events |
| Clopidogrel | P2Y12 platelet function assay (VerifyNow P2Y12) | PRU <208 suggests adequate inhibition; >230 = high on-treatment reactivity | CYP2C19 poor metabolizers, recurrent events, suspected non-adherence |
| Clopidogrel | CYP2C19 genotyping | *2/*2, *2/*3, *3/*3 = poor metabolizers | Consider alternative (ticagrelor, prasugrel) if loss-of-function alleles |
| Warfarin | INR (PT/INR) | Target INR 2.0–3.0 (most indications); 2.5–3.5 (mechanical valves) | Routine monitoring required; narrow therapeutic window |
| Apixaban | Anti-Xa assay (apixaban-calibrated) | Drug-specific calibration required; trough >50 ng/mL suggests therapeutic level | Suspected accumulation (renal impairment), bleeding, recurrent events, adherence |
| Rivaroxaban | Anti-Xa assay (rivaroxaban-calibrated) | Peak levels vary by dose; trough detectable confirms recent intake | Similar to apixaban; timing relative to dose matters |
| Dabigatran | Dilute thrombin time (dTT), Ecarin clotting time (ECT) | Prolonged dTT/ECT confirms drug presence; quantitative assays available | Pre-procedure assessment, bleeding, suspected accumulation |
| Heparin (UFH) | Anti-Xa assay or aPTT | Anti-Xa 0.3–0.7 IU/mL (therapeutic); aPTT 1.5–2.5× control | Routine monitoring for IV heparin infusion |
| LMWH (enoxaparin) | Anti-Xa assay | Peak (4h post-dose): 0.5–1.0 IU/mL (BID) or 1.0–2.0 IU/mL (daily) | Obesity, renal impairment, pregnancy, extremes of weight |
Note: Routine monitoring of DOACs is not recommended, but targeted testing is valuable in specific scenarios. PT/INR and aPTT are affected by DOACs and should not be used to assess their therapeutic effect.
Part IV: Hypercoagulable Panel
🔹 When to Order a Hypercoagulable Panel
- Ischemic stroke in young patient (<50 years) without clear etiology
- Cryptogenic stroke with venous features: concurrent DVT/PE, history of VTE, pregnancy losses
- Cerebral venous thrombosis or unusual clot locations (splanchnic, upper extremity)
- Recurrent arterial events despite appropriate antithrombotic therapy
- Clinical features suggesting APS: livedo reticularis, recurrent miscarriages, prolonged aPTT, valve vegetations
- Family history of unprovoked VTE or arterial thrombosis at young age
- Do NOT routinely order in typical elderly stroke with clear atherosclerotic or cardioembolic etiology
Hypercoagulable Panel Components
| Test | Condition Detected | Notes |
|---|---|---|
| Antiphospholipid Syndrome (APS) — Highest Yield for Arterial Stroke | ||
| Lupus anticoagulant (LA) | APS | Most specific for thrombosis; affected by anticoagulants—test before starting or after washout |
| Anticardiolipin antibodies (IgG, IgM) | APS | Medium-high titers clinically significant; can test on anticoagulation |
| Anti-β2-glycoprotein I (IgG, IgM) | APS | Most specific antibody; triple-positive (all 3) = highest risk |
| Inherited Thrombophilias — Primarily Venous Risk | ||
| Factor V Leiden mutation | Activated protein C resistance | Most common inherited thrombophilia; mainly venous risk; arterial role debated |
| Prothrombin G20210A mutation | Elevated prothrombin levels | Second most common; primarily venous thrombosis |
| Protein C activity | Protein C deficiency | Decreased in acute thrombosis, liver disease, warfarin use—recheck when stable |
| Protein S activity (free) | Protein S deficiency | Affected by pregnancy, OCP, acute illness, warfarin—timing matters |
| Antithrombin III activity | Antithrombin deficiency | Decreased by heparin, acute thrombosis, liver disease; heparin resistance if deficient |
| Other Tests | ||
| Homocysteine | Hyperhomocysteinemia | Elevated levels associated with stroke; B-vitamin supplementation reduces levels but not events (VITATOPS) |
| Factor VIII activity | Elevated factor VIII | Persistently elevated levels (>150%) associated with VTE recurrence |
Timing considerations: Acute thrombosis, anticoagulation, and illness affect many results. Protein C, protein S, and antithrombin are best tested when clinically stable and off anticoagulation (or on stable warfarin for protein C/S). Lupus anticoagulant requires testing off heparin/DOACs. Anticardiolipin and anti-β2GP1 can be tested on anticoagulation. Confirm positive results at least 12 weeks apart for APS diagnosis.
Part V: Specialized Testing for Rare Etiologies
When clinical features suggest a specific rare diagnosis, targeted testing can be diagnostic. The table below summarizes key clinical scenarios and corresponding investigations.
| Clinical Scenario | Consider | Key Testing |
|---|---|---|
| Young adult, recurrent posterior circulation strokes, basilar dolichoectasia, renal insufficiency, cardiomyopathy, acroparesthesias, angiokeratomas | Fabry disease | Alpha-galactosidase A enzyme activity (males); genetic testing (GLA gene); Lyso-Gb3 (globotriaosylsphingosine) biomarker |
| Young African American or Caribbean descent, moyamoya pattern on imaging, childhood stroke history, hemolytic anemia | Sickle cell disease | Hemoglobin electrophoresis; CBC with reticulocyte count; peripheral smear |
| Young adult, strokes not respecting vascular territories, cortical predilection, history of migraine, seizures, sensorineural hearing loss, short stature, elevated lactate | MELAS (mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes) | Serum and CSF lactate; genetic testing: mtDNA analysis (m.3243A>G most common) + whole exome sequencing; muscle biopsy (ragged red fibers) |
| Young adult, stroke-like episodes, basal ganglia calcifications on CT, seizures, progressive external ophthalmoplegia | POLG-related disorders (MELAS-like) | POLG gene sequencing; mtDNA analysis; serum lactate; consider muscle biopsy |
| Multiterritory infarcts, markedly elevated D-dimer, unexplained weight loss, migratory thrombophlebitis | Trousseau syndrome (occult malignancy) | D-dimer; CT chest/abdomen/pelvis; age-appropriate cancer screening (colonoscopy, mammogram, PSA); consider PET-CT if high suspicion |
| Young patient, ESUS, prior miscarriages or stillbirths, history of DVT/PE, livedo reticularis, prolonged aPTT, cardiac valve vegetations | Antiphospholipid syndrome | Lupus anticoagulant, anticardiolipin Ab, anti-β2GP1 Ab; confirm positivity at 12 weeks; TRAPS: warfarin superior to rivaroxaban in triple-positive APS |
| Older patient (>50), new headache, jaw claudication, visual changes, scalp tenderness, elevated inflammatory markers | Giant cell arteritis | ESR, CRP; temporal artery biopsy; temporal artery ultrasound (“halo sign”); do NOT delay steroids for biopsy |
| Young stroke, multifocal stenoses, systemic inflammation, encephalopathy, headache, CSF pleocytosis | CNS vasculitis (primary or secondary) | CSF analysis (cells, protein, OCBs); ESR, CRP, ANA, ANCA; vessel wall MRI; DSA (beading); brain/leptomeningeal biopsy if needed |
| Young patient, stroke with skin lesions, livedo racemosa, cognitive decline, no inflammation | Sneddon syndrome | Skin biopsy (endothelial proliferation, thrombosis of medium vessels); APS workup; vessel wall MRI |
| Stroke with cocaine or amphetamine use, severe hypertension, vasoconstriction on imaging | Drug-induced vasospasm/vasculitis | Urine drug screen; vessel imaging (CTA/MRA may show beading or vasoconstriction) |
Genetic Testing for Mitochondrial Disease
When MELAS or other mitochondrial disorders are suspected, comprehensive genetic testing includes:
- mtDNA point mutation analysis: Targets common mutations (m.3243A>G accounts for ~80% of MELAS)
- mtDNA deletion/duplication analysis: For suspected Kearns-Sayre or other deletion syndromes
- Whole exome sequencing (WES): Identifies nuclear gene mutations affecting mitochondrial function (POLG, TWNK, etc.)
- mtDNA whole genome sequencing: Comprehensive mitochondrial genome analysis
Testing can be performed on blood, though heteroplasmy levels vary by tissue. If blood testing is negative but clinical suspicion remains high, consider testing urine sediment or muscle biopsy tissue where mutation load may be higher.
CSF Analysis
Lumbar puncture is indicated when CNS vasculitis, infection, or inflammatory conditions are suspected:
- Cell count: Pleocytosis (lymphocyte-predominant) in vasculitis, infection
- Protein: Elevated in inflammation, infection, malignancy
- Glucose: Low in bacterial/fungal infection, carcinomatous meningitis
- Oligoclonal bands: Present in MS, neurosarcoidosis, some vasculitides
- Lactate: Elevated in MELAS (>2.2 mmol/L), bacterial meningitis
- Cytology/flow cytometry: If lymphoma or carcinomatous meningitis suspected
- Infectious studies: HSV PCR, VZV PCR, fungal cultures/antigens as indicated
Part VI: Summary — What to Order When
| Clinical Context | Laboratory Tests |
|---|---|
| All ischemic stroke patients | Lipid panel (fasting preferred), HbA1c, BMP, CBC, PT/INR |
| Atherosclerotic stroke (LAA) | Above + consider Lp(a), hs-CRP if risk stratification needed |
| Cryptogenic stroke, age <50 | Above + hypercoagulable panel (APS antibodies priority), consider Lp(a), drug screen |
| Suspected APS | Lupus anticoagulant, anticardiolipin IgG/IgM, anti-β2GP1 IgG/IgM; confirm at 12 weeks |
| Suspected Trousseau/malignancy | D-dimer, CBC, CMP, LDH, age-appropriate cancer screening, CT CAP, consider PET |
| Suspected GCA | ESR, CRP, CBC (thrombocytosis, anemia); proceed to biopsy, do not delay steroids |
| Suspected CNS vasculitis | ESR, CRP, ANA, ANCA, complement; CSF analysis; consider vessel wall MRI, DSA |
| Suspected MELAS | Serum lactate, CSF lactate; mtDNA analysis + WES; consider muscle biopsy |
| Suspected Fabry disease | Alpha-galactosidase A activity; GLA gene sequencing; Lyso-Gb3 biomarker |
| Recurrent stroke on antithrombotic | Verify adherence; platelet function assay (if on antiplatelet); anti-Xa or INR (if on anticoagulant); CYP2C19 genotype (if on clopidogrel) |
References
- Amarenco P, et al. A comparison of two LDL cholesterol targets after ischemic stroke (TST). N Engl J Med. 2020;382:9-19.
- Amarenco P, et al. High-dose atorvastatin after stroke or transient ischemic attack (SPARCL). N Engl J Med. 2006;355:549-559.
- Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). N Engl J Med. 2008;359:2195-2207.
- Pengo V, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome (TRAPS). Blood. 2018;132:1365-1371.
- Grant EG, et al. Society of Radiologists in Ultrasound Consensus Conference on carotid stenosis. Radiology. 2003;229:340-346.
- Miyatake S, et al. Clinical determinants of stroke-like episodes in MELAS. J Neurol. 2011;258:2073-2079.
- Schiffmann R, et al. Fabry disease. Handb Clin Neurol. 2015;132:231-248.
- Arnett DK, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140:e596-e646.